AcelRx Pharmaceuticals (ACRX) Reports In-Line Q3 Loss of 38c/Share

AcelRx Pharmaceuticals (NASDAQ: ACRX) reported Q3 EPS of ($0.38), in-line with the analyst estimate of ($0.38). Revenue for the quarter came in at $166 thousand versus the consensus estimate of $320 thousand.

For earnings history and earnings-related data on AcelRx Pharmaceuticals (ACRX) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• HSBC Downgrades China Power International (2380:HK) (CPWIF) to Hold
• Ross Stores, Inc. (ROST) PT Raised to $240 at Bernstein SocGen Group